• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

AbbVie preps filings for lymphoma bispecific licensed from Genmab

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 14, 2022 at 10:42: AM
via Two years after signing a $3.9 billion alliance with Genmab to find new cancer therapies, AbbVie has said it is ready to start talking to regulators about filing for approval of the lead drug in the partnership – epcoritamab for large B-cell lymphoma (LBCL).

article source
 




Top Bottom
Back
Quote